Sustained and rapid improvements in patient reported outcomes for moderate-to-severe psoriasis patients with moderate and high BSA treated with ixekizumab: Side-by-side results from UNCOVER-3 and IXORA-S

被引：0
|
作者：
Bagel, Jerry [1 ]
Gottlieb, Alice B. [2 ]
Burge, Russel [3 ,4 ]
See, Kyoungah [3 ]
Garrelts, Alyssa [3 ]
McKean-Matthews, Missy [5 ]
Papp, Kim [6 ]
机构：
[1] Psoriasis Treatment Ctr Cent NJ, East Windsor, NJ USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Univ Cincinnati, Cincinnati, OH USA
[5] Syneos Hlth, Raleigh, NC USA
[6] Prob Med Res, Waterloo, ON, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
26032
引用
收藏
页码：AB82 / AB82
页数：1
相关论文
共 50 条
  • [21] Maintenance of efficacy results from UNCOVER-1: A phase 3 trial of ixekizumab for moderate-to-severe plaque psoriasis
    Leonardi, Craig
    Blauvelt, Andrew
    Langley, Richard
    Luger, Thomas
    Ohtsuki, Mamitaro
    Cameron, Gregory S.
    Braun, Daniel
    Erickson, Janelle
    Zhao, Fangyi
    Shrorn, David S.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian
    Gordon, Kenneth
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S16 - S16
  • [22] Treatment with ixekizumab over 60 weeks provides sustained improvements in work productivity and activity levels: Results from UNCOVER-1, a phase 3 trial in patients with moderate-to-severe psoriasis
    Armstrong, April W.
    Fretzin, Scott
    McBride, Sandy R.
    Burge, Russel
    Zhu, Baojin
    Edson-Heredia, Emily
    Zhao, Fangyi
    Beselin, Anke
    Gordon, Kenneth
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB280 - AB280
  • [23] Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, phase III clinical trial (UNCOVER-3)
    Blauvelt, Andrew
    Gooderham, Melinda
    Iverson, Lars
    Ball, Susan
    Agada, Noah
    Zhang, Lu
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB112 - AB112
  • [24] Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
    Blauvelt, Andrew
    Gooderham, Melinda
    Iversen, Lars
    Ball, Susan
    Zhang, Lu
    Agada, Noah O.
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (05) : 855 - 862
  • [25] Continued treatment with ixekizumab over 60 weeks provides sustained improvements in work productivity and activity levels: results from UNCOVER-2, a Phase 3 trial in patients with moderate-to-severe psoriasis
    Lynde, C.
    McBride, S.
    Stahle, M.
    Burge, R.
    Lin, C. -Y.
    Amato, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 69 - 70
  • [26] Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)
    Menter, A.
    Warren, R. B.
    Langley, R. G.
    Merola, J. F.
    Kerr, L. N.
    Dennehy, E. B.
    Shrom, D.
    Amato, D.
    Okubo, Y.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (10) : 1686 - 1692
  • [27] Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study
    Lebwohl, M. G.
    Gordon, K. B.
    Gallo, G.
    Zhang, L.
    Paul, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (02) : 301 - 309
  • [28] The impact of ixekizumab treatment on health-related quality of life in patients with moderate-to-severe psoriasis: results from UNCOVER-1
    Augustin, M.
    Gordon, K.
    Nikai, E.
    Edson-Heredia, E.
    Zhu, B.
    Goldblum, O. M.
    Carlier, H.
    Langley, R. G.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 (03) : E9 - E9
  • [29] Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study (UNCOVER-1)
    Gordon, Kenneth
    Blauvelt, Andrew
    Langley, Richard
    Luger, Thomas
    Ohtsuki, Mamitaro
    Cameron, Gregory S.
    Braun, Daniel K.
    Erickson, Janelle
    Zhao, Fangyi
    Shrom, David S.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian
    Leonardi, Craig
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S6 - S6
  • [30] Improvement in touch avoidance in patients with genital psoriasis treated with ixekizumab: 52-week results of a phase 3 clinical trial in patients with moderate-to-severe genital psoriasis (IXORA-Q)
    Soung, Jennifer
    Cather, Jennifer Clay
    Gooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB69 - AB69
12345